Case report: Eli Lilly loses latest Alimta battle

In the latest instalment of the long-running patent dispute between Actavis and Eli Lilly in relation to anti-cancer drug Alimta (pemetrexed disodium), in February 2016 Mr Justice Arnold at the English High Court handed down his judgment on the issues remitted to him by the English Court of Appeal.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Novo Nordisk and OpenAI strike AI deal to boost drug discovery

15 April 2026 The Danish pharma giant is turning to artificial intelligence as it faces patent expiry, falling shares and intensifying competition from Eli Lilly.

Big Pharma

Part II: The race to replace semaglutide heats up

23 March 2026 With Novo Nordisk's core semaglutide patent expired in India last week, the company that built one of the most successful drugs in pharmaceutical history is already fighting on a new front. So what comes next?

Big Pharma

Sandoz strikes fresh biosimilar deal with South Korean biotech

19 March 2026 The Swiss generics giant secures global commercialisation rights as partnership targets multi-billion-dollar loss-of-exclusivity opportunity.

More features

INTA 2026: In-house tips on what to do in London

Baker McKenzie strengthens IP bench with new German lead

Novo Nordisk and OpenAI strike AI deal to boost drug discovery

IP finance gap risks startup exodus, EUIPO warns

Patent office fee increases: What applicants must know

LSPN Awards USA: Meet the judges

UK patent office adopts EPO standards for AI inventions

Gilead to pay up to $5bn for antibody-drug conjugates push

Case report: Eli Lilly loses latest Alimta battle

More on this story

Editor's picks

Editor's picks

More features